Viewing Study NCT00054756



Ignite Creation Date: 2024-05-05 @ 11:29 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00054756
Status: COMPLETED
Last Update Posted: 2018-08-08
First Post: 2003-02-07

Brief Title: Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization: National Institutes of Health Clinical Center CC

Study Overview

Official Title: Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities
Status: COMPLETED
Status Verified Date: 2018-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone TRH a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities Normal thyroid gland function depends on proper chemical signaling between the thyroid gland the hypothalamus the part of the brain where TRH is made and the pituitary another part of the brain The TRH test helps assess this interaction Production of the only FDA-approved preparation of TRH was stopped in July 2002 As a result to have a continuous source of TRH available for NIH clinical and research purposes the NIH Clinical Center CC Pharmacy Department produced a pharmaceutical grade formulation of TRH for patient use This study will test the CC formulation in healthy volunteers to show that its activity and side effects are similar to those of the previously available commercial test preparation It will then be studied in CC patients for whom the diagnostic test is recommended

Healthy volunteers between 18 and 65 years of age and all patients requiring TRH evaluation of hypothalamic-pituitary-thyroid gland interaction may be eligible for this study Patients include those with pituitary reserve inconsistent thyroid function test inappropriate TSH secretion or pre- and post-operative evaluation of pituitary tumors Normal volunteers will be screened with a medical history physical examination and blood tests Women of child-bearing potential will be given a pregnancy test pregnant and breast-feeding women may not participate

The TRH test procedure will be the same for healthy volunteers and patients All participants fast from midnight before the morning of the test In the morning a catheter flexible plastic tube is inserted into an arm vein for easy injection of the TRH and collection of blood samples Blood pressure is monitored before and during the test A blood sample is drawn and then TRH is given through the catheter over a 1-minute period Another nine blood samples are collected over a 3-hour period from the time of the TRH injection for measuring levels of various hormones A total of less than 4 tablespoons of blood is taken for the test
Detailed Description: Thyrotropin releasing hormone TRH is a neuropeptide used in the diagnostic evaluation of patients with dysfunction of the hypothalamic-pituitary-thyroid HPT axis In healthy individuals administration of TRH intravenously results in pituitary secretion of thyrotropin thyroid-stimulating hormone TSH which in turn stimulates the thyroid gland release of thyroid hormones thyroxine T4 and triiodothyronine T3 TRH stimulates the secretion of other pituitary hormones under normal physiologic as well as pathologic conditions

Under this protocol TRH is used for routine diagnostic testing and research studies in adults and children It is produced by the Pharmaceutical Development Section of the Clinical Center Pharmacy at the NIH The safety activity and comparability of this preparation were demonstrated in a small group of normal volunteers prior to its release for diagnostic and research use

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
03-DK-0098 OTHER NIHCC None